Treatment & Research Archives

January 24, 2023

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

Dr. Sun was interviewed by Dr. Brian Koffman, a physician, CLL patient, and executive vice president and chief medical officer of CLL Society, at the ASH 2022 meeting in New Orleans. In the interview, she elaborates on the research results and recommendations on how patients can avoid cardiac issues

January 24, 2023

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical

January 6, 2023

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

Fixed-duration ibrutinib plus venetoclax provides an overall survival advantage and better sustained progression-free survival regardless of measurable residual disease (MRD) status compared with chlorambucil plus obinutuzumab as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

January 6, 2023

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with

December 29, 2022

ASH 2022: Dr. Jennifer Brown on Zanubrutinib vs. Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL)

In this interview, Dr. Brian Koffman interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the ALPINE trial, a phase 3 clinical trial directly comparing the efficacy of zanubrutinib vs. ibrutinib in patients with relapsed/refractory

November 18, 2022

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

The combination of obinutuzumab (Gazyva), acalabrutinib (Calquence), and venetoclax (Venclexta) failed to meet the pre-specified rate of undetectable measurable or minimal residual disease (uMRD) following optimal debulking with bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

November 18, 2022

ASH 2021: Increased Risk for Serious Infections Linked with Monoclonal B-Cell Lymphocytosis

Patients with monoclonal B-cell lymphocytosis (MBL), a precursor to chronic lymphocytic leukemia (CLL), were at increased risk of severe infections, according to an analysis of records from participants collected in the Mayo Clinic Biobank.

November 18, 2022

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL/SLL.

November 14, 2022

Depletion of CLL Cells by Venetoclax Treatment Reverses Oxidative Stress and Impaired Glycolysis in CD4 T cells

Our immune system is a complex organization of lymphocytes, myeloid cells (granulocytes, macrophages, dendritic cells), complement factors, cytokines, and other chemical mediators, which all work together to fend off disease and infection.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Treatment & Research

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

ASH 2022: Dr. Jennifer Brown on Zanubrutinib vs. Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL/SLL)

Obinutuzumab/Acalabrutinib/Venetoclax Combo Misses the Mark for MRD in Advanced Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Increased Risk for Serious Infections Linked with Monoclonal B-Cell Lymphocytosis

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Depletion of CLL Cells by Venetoclax Treatment Reverses Oxidative Stress and Impaired Glycolysis in CD4 T cells

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT